# Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

> **NCT03670069** · PHASE1 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Metastatic Leiomyosarcoma
- Metastatic Synovial Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Advanced Myxoid Liposarcoma
- Advanced Soft Tissue Sarcoma
- Metastatic Myxoid Liposarcoma
- Metastatic Round Cell Liposarcoma
- Metastatic Soft Tissue Sarcoma
- Refractory Leiomyosarcoma
- Refractory Myxoid Liposarcoma
- Refractory Round Cell Liposarcoma
- Refractory Soft Tissue Sarcoma
- Refractory Synovial Sarcoma
- Refractory Undifferentiated Pleomorphic Sarcoma
- Advanced Leiomyosarcoma
- Advanced Synovial Sarcoma
- Advanced Undifferentiated Pleomorphic Sarcoma
- Metastatic Chondrosarcoma

## Interventions

- **DRUG:** Itacitinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03670069
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-30
- **Primary completion:** 2023-03-04
- **Final completion:** 2024-05-06
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was multifactorial, including slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit.
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03670069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03670069, "Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03670069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*